Ovarian Cancer, Platinum-resistant Ovarian Cancer
Conditions
Brief summary
Phase II, two arm prospective study of efficacy and safety of ELENAGEN in combination with gemcitabine in comparison with gemcitabine alone in patients with platinum-resistant ovarian cancer.
Detailed description
The purpose of this clinical study is to evaluate safety and efficacy of ELENAGEN, a novel anticancer therapeutics (plasmid DNA encoding p62/SQSTM1) protein, as an adjuvant to chemotherapy with Gemcitabin (GEM) in patients with advanced platinum-resistant ovarian cancer. This is a prospective randomized multi-center study with two arms. Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks) is administered in both arms: In the Chemo arm (n = 20) Gemcitabine is the only treatment, and in the ELENAGEN arm (n = 20) GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly). The primary endpoint is progression-free survival (PFS), and the secondary endpoint is safety.
Interventions
DRUGGemcitabine
Chemotherapeutics
BIOLOGICALELENAGEN
DNA plasmid
Sponsors
CureLab Oncology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This was a prospective randomized multi-center study with two arms. Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks) was administered in both arms: In the Chemo arm (n = 20) GEM was the only treatment, and in the ELENAGEN arm (n = 20) GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly).
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* The patient is 18-70 years old. * Written informed consent of the patient to participate in clinical trials. * Presence of histologically confirmed ovarian cancer. * The return of the disease occurred less than 6 months after the last administration of platinum. * Presence of measurable tumor lesions according to RECIST 1.1 criteria. * Functional status according to ECOG scale is 0-2. * Life expectancy of at least 6 months. * Adequate function of the organs as determined by the following criteria: 1. Absolute number of neutrophils (ANN) ≥1500/mm3 (≥1.5 × 109/l); 2. Platelet count ≥100,000/mm3 (IU: ≥100 × 109/l). 3. Hemoglobin level ≥ 9.0 g/dL determined by analysis performed at least 2 weeks after the last hemotransfusion; 4. The level of AST and ALT in blood serum not exceeding more than 3 times the upper limit of the norm. 5. The level of serum bilirubin not exceeding more than 1.5 times the upper limit of normal. 6. Serum Creatinine ≤ 1.5 mg/dL. * The ability of the patient to follow the directions of the research physician and follow the study regimen.
Exclusion criteria
Criteria by which patients are not included in the study * Platinum-sensitive relapse of ovarian cancer (disease recurrence occurred more than 6 months after the last administration of platinum drugs). * Presence of serious diseases or health conditions: 1. Other malignancies, with the exception of malignancies treated more than 5 years ago without signs of return of the disease. 2. Brain metastases or leptomeningeal metastases. 3. Active infection (e.g. fever ≥38 °C), including active or unresolved pneumonia/pneumonitis. 4. Uncontrolled diabetes mellitus. 5. Myocardial Infarction in the last 12 months, severe/unstable angina, clinically manifested heart failure class III-IV according to the classification of the New York Cardiology Association (NYCA). 6. Gastrointestinal bleeding within the last 2 weeks. 7. Human immunodeficiency virus (HIV), chronic or acute hepatitis B or hepatitis C. 8. Patients with autoimmune disorders or organ transplantation who require immunosuppressive therapy. I. Mental illness that may increase the risk associated with participation in the study or taking the study drug or that may affect the interpretation of the results of the study. K. Polyallergy, bronchial asthma (including aspirin) in history. * Major surgery during the previous 4 weeks (complete wound healing). * Previous chemotherapeutic treatment of the patient according to the scheme GEMCITABINE * Radiotherapy with extended field radiation within the previous 4 weeks or radiotherapy with a limited field radiation within the previous 2 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | 2 years since the start of treatment | Median duration of time from start of treatment to time of progression by RESIST 1.1 criterion or death. Progression is defined using RECIST v 1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of Elenagen in Combination With Gemcitabine | 1 year after the start of treatment | Frequency of drug-related adverse events (AEs) and serious AEs (SAEs) according to NCI CTCAE version 5.0. |
Countries
Belarus
Participant flow
Recruitment details
All patients were recruited in medical clinics of Republic of Belarus,
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 40 Participants |
| CA125 oncomarker | 116 units per ml |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 40 Participants |
| Region of Enrollment Belarus | 40 Participants |
| Sex: Female, Male Female | 40 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 20 | 1 / 20 |
| other Total, other adverse events | 4 / 20 | 7 / 20 |
| serious Total, serious adverse events | 0 / 20 | 0 / 20 |
Outcome results
None listed